Peer Review History

Original SubmissionApril 16, 2021
Decision Letter - Amitava Mukherjee, Editor

PONE-D-21-11593

Biosafety devices to control the spread of potentially contaminated dispersion particles. New associated strategies for health environments.

PLOS ONE

Dear Dr. Montalli,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 25 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Amitava Mukherjee, ME, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

(Research Productivity Fellowships was awarded to MHN), Coordenação de

Aperfeiçoamento de Pessoal de Nível Superior, CAPES (#001)"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The author(s) received no specific funding for this work."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Competing Interests section:

"The authors have declared that no competing interests exist."

We note that one or more of the authors are employed by a commercial company: UVCtec Company.

3.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

3.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

4. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables should remain uploaded as separate "supporting information" files.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study has been rigously performed and reported. The paper needs to be proof read. Grammatical errors have been noticed, 98-102; 279-81. Statistical equations could be elaborated. Limitations of the study need to be addressed.

Reviewer #2: It is an important concern about the aerosol spread in dental therapy and operation especially in the background of the COVID-19 pandemic. I commend the authors’ effort on experimental investigation on airborne bioaerosol control during a simulation drill operation. But there are still important issues which I strongly recommend the authors think about and make improvement.

Major issue 1: Organization of the paper

Comment 1. The organization and the citation of the figures in this manuscript is really confusing to the readers. Just for two examples:

a) The citation of Figure 1 in Line 146 and Line 199 indicate the figure should be the illustration of the test environment and sampling location. But the Figure 1 is actually the CFU measurement results.

b) Both Figure 4 and Figure 4(supplementary) cannot support the citation in Line 295 to Line 299 of the manuscript.

Comment 2. Some experiments mentioned in material and methods. But the corresponding results and discussion are missing. For an example, I did not find the results and discussion about PCDP suspension in the dental clinical room and presence measurement outside the clinical room.

Major issue 2: Validation of the experiment. And Connection between the object and supporting data

Comment 3. The topic of this manuscript is about the control the spread of bioaerosols in health environment. But the experiments were just actually designed to validate the bioaerosol concentration control. The emission sources were placed on all available dental chairs rather than part of the chairs or maybe just one chair. The results of the measurement outside the clinic room are missing. It is impossible for readers to evaluate the control effect of bio-particles spread of the measures mentioned in the paper. On the other hand, the authors should also make introductions on if such strategies or measures could be applied in other health care environment as specified in the tittle.

Comment 4. In the negative control group (Line 279 to 284), the petri dishes indicated wide contamination. The largest observation is 11.3 (6.1) for IBBD group. It is not normal according to my previous research experience and indicate the dishes are not well protected or the preparation did not fulfil the requirements of aseptic operation.

Major issue 3: Limitation of the biosafety risk of UV technology

Comment 5. UV technology is one of most traditional, easily available and widely used disinfection technology. But there are also concerns about the biosafety risk especially for short term radiation, such as 15min in this manuscript. Major concerns include:

a) Variation might happen to the pathogens after UV radiation.

b) The biggest concern is about the pathogen variation on the resistance for antibiotic.

According to a 12 months airborne bacterial monitoring in a hospital in 2004 in Guangxi, China (Yanhua Chen, Hui Li, Yiping Lu and Lingsha Huang, Distribution of bacteriological spectrum in the air of hospital and analysis of their drug resistance, Chinese Journal of Antibiotics, 2006, 31(008):505-506 (in Chinese)):

a) 450 bacterium strains were collected during 833 samplings in 90 locations

b) 72.0% show resistance to penicillin

c) 76.9% show resistance to ampicillin

d) Above 40% show resistance to new antibiotics such as cephalosporins and quinolones

e) The drug-resistance rate in the hospital is much higher than the other monitoring results in communities, which is believed highly relatedly with the wide use the UV disinfection instruments in hospitals in underdeveloped area

Another research published in 2010 (Yan Wang, Yao Zhou and Yinghua Zhang et al., Impact of Ultraviolet Irradiation on Bacterial Drug Resistance, Chinese Journal of Nosocomiology, 2010, 020(021):3355-3356,3363. (in Chinese)) indicate obvious change drug resistance of Serratia marcescens on amoxicillin, aztreonam and cefuroxime after short term UV irradiation and generation multiplication.

I would recommend that the authors make necessary analysis about the minimum dose of the UV radiation, and consider the possibility of extending the radiation time. Or list the related risk and concerns.

Major issue 4: English expression of the paper

Comment 6. I am not a native English speaker. But there are obvious errors in some sentences and expressions such as “The radiometer was operated with specified precision at room temperature of 22°C to 53% relative humidity” in Line 215 to 216. These would cause confusion and misunderstanding of readers. So, I recommend the authors re-check the expression and fix all errors.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Bhanu Lakhani

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

June 20th 2021.

Dr. Joerg Heber

Editor-in-Chief, Plos One

Please find enclosed a copy of our reviewed manuscript PONE-D-21-11593, "Biosafety devices to control the spread of potentially contaminated dispersion particles. New associated strategies for health environments". We would like to thank you and the reviewers for all constructive comments and we are certain that they were key to improve the manuscript. We accepted most of the suggestions and added information to the text to clarify the points raised by the referees. All changes performed in the manuscript were highlighted in red. Our responses to the individual comments are delineated below. We hope that these corrections will satisfy the reviewer’s comments, and look forward to hearing from you.

Sincerely yours,

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

A: Thank you for your suggestion. We have included additional information in the manuscript in order to strengthen the transmission. Please see new submitted version of the manuscript.

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

(Research Productivity Fellowships was awarded to MHN), Coordenação de

Aperfeiçoamento de Pessoal de Nível Superior, CAPES (#001)"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The author(s) received no specific funding for this work."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

A: Thank you for your careful reading. We have removed the funding from the acknowledgment section and updated the Funding statement. We believe it is important to highlight the unspecific funding because the funding described (CAPES #001) refers to the www.periodicos.capes.gov.br which is the Brazilian national electronic library consortium for science and technology, providing full access to the content of more than 10,000 journals. Since only universities which possess master and PhD programs have access of this consortium, we provide this recognition. On the other hand, the CNPq is an individual fellowship granted to Dr. Marcelo Henrique Napimoga. Thus, none of the funding named here was used to support the current experiments.

3. Thank you for stating the following in the Competing Interests section:

"The authors have declared that no competing interests exist."

We note that one or more of the authors are employed by a commercial company: UVCtec Company.

3.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

A: Thank you for your careful reading. Mr. Oscar F. Torres-Junior who has affiliation with UVCtec company helped with the calculation of UV-C radiation in the studied environment as already described in the first submission. We have updated the Funding statement to describe that UVCtec company is a startup and the equipment UMDUV 2.0 is a Minimum Viable Product (MVP) prototype. Mr. Oscar Torres-Junior has support in the form of salary. None of the other authors has received any funding or has any commercial interest with UVCTec.

3.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

A: The conflict of interest already provide the information requested. We have included that Mr. Oscar Torres-Junior has support in the form of salary from UVCTec, although this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

4. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables should remain uploaded as separate "supporting information" files.

A: Thank you for your careful reading. We have provided the corrections.

Reviewers' comments:

Reviewer #1: The study has been rigously performed and reported. The paper needs to be proof read. Grammatical errors have been noticed, 98-102; 279-81. Statistical equations could be elaborated. Limitations of the study need to be addressed.

A: Thank you for your careful reading. Below the new information included in the revised manuscript. Please see new submitted version of the manuscript.

98-102:

“Among microorganisms that are potentially contagious to health professionals operating near the face and oral cavity, especially when PCDP is generated [10], are hepatitis B virus, HIV (human immunodeficiency virus).as well as SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2). The latter can remain infectious in aerosols for long periods, even when water evaporates, and particles that settle on surfaces can remain infectious for up to 72 h [8, 9].”

279-81:

“From the Petri dishes arranged in dental clinics before the beginning of the tests, the negative control group had low CFU counts. The group without barriers had mean (standard deviation) of 1.3 (1.0) CFU; the IBBD group 11.3 (6.1); the UV-C group 1.0 (0.8) and in the IBBD + UV-C group 2.3 (2.1), with no statistically significant difference (p>0.05) between the dental clinics used for the experiments.”

Limitations of the study was addressed in the discussion:

“Our study has some limitations, including no assessments for potential adverse effects on plastics were conducted. Furthermore, because irradiance and dosages were determined using a single UV-C device, our findings cannot be considered representative of all such devices. Other systems currently available differ in the type and size of UV-C bulbs utilized, the type of reflective surfaces behind bulbs, and methods for monitoring UV-C dosage. We did not evaluate the ability of the UV-C device to reduce bacterial levels on high-touch surfaces or to reduce healthcare-associated infections.”

Reviewer #2: It is an important concern about the aerosol spread in dental therapy and operation especially in the background of the COVID-19 pandemic. I commend the authors’ effort on experimental investigation on airborne bioaerosol control during a simulation drill operation. But there are still important issues which I strongly recommend the authors think about and make improvement.

Major issue 1: Organization of the paper

Comment 1. The organization and the citation of the figures in this manuscript is really confusing to the readers. Just for two examples:

a) The citation of Figure 1 in Line 146 and Line 199 indicate the figure should be the illustration of the test environment and sampling location. But the Figure 1 is actually the CFU measurement results.

b) Both Figure 4 and Figure 4(supplementary) cannot support the citation in Line 295 to Line 299 of the manuscript.

A: Thank you for your careful reading. We have included additional information in the citation of the figures. Please see new submitted version of the manuscript.

Comment 2. Some experiments mentioned in material and methods. But the corresponding results and discussion are missing. For an example, I did not find the results and discussion about PCDP suspension in the dental clinical room and presence measurement outside the clinical room.

A: The data regarding this issue was provided in the first submission as described below:

Results section

To evaluate the distance that PCDP can reach from the generating source, new Petri dishes were positioned in the corridor that connect the clinics to the end of the group test without barriers. As shown in Fig 2E, it was observed the growth of 903 (28) CFU in the plates positioned 1m from the input (yellow box), 3044 (64) CFU at 5m distance (dark orange box) and 1966 (42) CFU 10 m away from the generating source (light orange box). Schematic 3D data are presented in S5 Fig.

Discussion section

In addition, it is worth the attention to the high CFU count of the corridor from the droplet dispersion area (clinic without barriers). Measures should be taken to reduce both, the risk of contamination in the contaminated environment, and in environments that give access to critical areas of contamination. Furthermore, we noticed that 30 minutes after the end of the generation of PGDP, high numbers of CFU were found, and from 60 minutes, regardless of the use of barriers, there is a sharp drop in the number of counts, demonstrating the importance of microorganisms in suspension that can be sources of cross-transmission between individuals. Particles suspended in the air during and after dental care can reach the respiratory tract and connective membranes of dental professionals and patients who will be treated later [32] raising the risk of cross-infection, including the SARS-CoV-2 virus.

Major issue 2: Validation of the experiment. And Connection between the object and supporting data

A: The current issue raised by the referee is not a question which we can properly answer. As demonstrated, all experiments are well designed and described, as well as the statistical analysis.

Comment 3. The topic of this manuscript is about the control the spread of bioaerosols in health environment. But the experiments were just actually designed to validate the bioaerosol concentration control. The emission sources were placed on all available dental chairs rather than part of the chairs or maybe just one chair. The results of the measurement outside the clinic room are missing. It is impossible for readers to evaluate the control effect of bio-particles spread of the measures mentioned in the paper. On the other hand, the authors should also make introductions on if such strategies or measures could be applied in other health care environment as specified in the tittle.

A: Thank you for your careful reading. As described below the results of outside clinic is already provided in the results section as well as in the discussion. In the current manuscript, we have designed an experimental design to spread a high density of contaminated dispersion particles in a university dental environment which has 12 dental chairs. This environmental condition with a high concentration of microorganism dispersion allowed us to test whether the barriers used for the control (individual biosafety barrier in dentistry) and UV-C light would be able to prevent dispersion.

Since we tested the dispersion of microorganisms using 12 dental chairs at the same time, and Petri dishes were placed in various places within the same room, totaling 56 dishes in each room, including the light fixtures on the room ceiling, we can see the potential for dispersion generated in our proposed methodology, as well as the ability to avoid such dispersion using the proposed barriers. Thus, given such a great challenge induced by this methodology, we believe it is possible to extrapolate that the measures tested here can be extrapolated to other health environments.

We have included an additional paragraph in the introduction to expand the overview of the possible use of the strategies in other health environments.

“Ultraviolet disinfection technology can be used to supplement manual cleaning, and recently it has become an acceptable method of no-touch disinfection within healthcare facilities and is currently routinely used in disinfecting the hospital environment with HAI reduction having been demonstrated in previous studies [15-20].”

Comment 4. In the negative control group (Line 279 to 284), the petri dishes indicated wide contamination. The largest observation is 11.3 (6.1) for IBBD group. It is not normal according to my previous research experience and indicate the dishes are not well protected or the preparation did not fulfil the requirements of aseptic operation.

A: Thank you for your careful reading. The idea of this information is to demonstrate that prior to the beginning of the experiment there was no significant contamination of Lactobacillus casei in the test environment. However, to avoid misunderstanding we renamed this test by removing the negative control word.

Major issue 3: Limitation of the biosafety risk of UV technology

Comment 5. UV technology is one of most traditional, easily available and widely used disinfection technology. But there are also concerns about the biosafety risk especially for short term radiation, such as 15min in this manuscript. Major concerns include:

a) Variation might happen to the pathogens after UV radiation.

b) The biggest concern is about the pathogen variation on the resistance for antibiotic.

According to a 12 months airborne bacterial monitoring in a hospital in 2004 in Guangxi, China (Yanhua Chen, Hui Li, Yiping Lu and Lingsha Huang, Distribution of bacteriological spectrum in the air of hospital and analysis of their drug resistance, Chinese Journal of Antibiotics, 2006, 31(008):505-506 (in Chinese)):

a) 450 bacterium strains were collected during 833 samplings in 90 locations

b) 72.0% show resistance to penicillin

c) 76.9% show resistance to ampicillin

d) Above 40% show resistance to new antibiotics such as cephalosporins and quinolones

e) The drug-resistance rate in the hospital is much higher than the other monitoring results in communities, which is believed highly relatedly with the wide use the UV disinfection instruments in hospitals in underdeveloped area

Another research published in 2010 (Yan Wang, Yao Zhou and Yinghua Zhang et al., Impact of Ultraviolet Irradiation on Bacterial Drug Resistance, Chinese Journal of Nosocomiology, 2010, 020(021):3355-3356,3363. (in Chinese)) indicate obvious change drug resistance of Serratia marcescens on amoxicillin, aztreonam and cefuroxime after short term UV irradiation and generation multiplication.

I would recommend that the authors make necessary analysis about the minimum dose of the UV radiation, and consider the possibility of extending the radiation time. Or list the related risk and concerns.

A: Thank you for your careful reading. We have included additional information about the possible UV-C use and UV resistance microorganisms.

“Moreover, because UV irradiation increases mutations, UV irradiation can potentially induce UV-C resistance, as previously reported [33]. However, when the UV dose reaches high enough to kill the entire bacterial population, the emergence of a UV-resistant phenotype can be prevented, indicating that UV-C disinfection is a safe and effective measure to employ in clinical settings without being concerned about the appearance of UV resistance [34].”

33. Shoults DC, Ashbolt NJ. Decreased efficacy of UV inactivation of Staphylococcus aureus after multiple exposure and growth cycles. Int J Hyg Environ Health. 2019 Jan;222(1):111-116. doi: 10.1016/j.ijheh.2018.08.007.

34. Choi H, Chatterjee P, Hwang M, Stock EM, Lukey JS, Zeber JE, et al. Can multidrug-resistant organisms become resistant to ultraviolet (UV) light following serial exposures? Characterization of post-UV genomic changes using whole-genome sequencing. Infect Control Hosp Epidemiol. 2021 Mar 22:1-7. doi: 10.1017/ice.2021.51.

Major issue 4: English expression of the paper

Comment 6. I am not a native English speaker. But there are obvious errors in some sentences and expressions such as “The radiometer was operated with specified precision at room temperature of 22°C to 53% relative humidity” in Line 215 to 216. These would cause confusion and misunderstanding of readers. So, I recommend the authors re-check the expression and fix all errors.

A: Thank you for your careful reading. Below the new information included in the revised manuscript. Please see new submitted version of the manuscript.

215 to 216:

“The radiometer was operated according to its specification at room temperature of 22°C at 53% of air relative humidity.”

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Amitava Mukherjee, Editor

Biosafety devices to control the spread of potentially contaminated dispersion particles. New associated strategies for health environments.

PONE-D-21-11593R1

Dear Dr. Montalli,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Amitava Mukherjee, ME, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Formally Accepted
Acceptance Letter - Amitava Mukherjee, Editor

PONE-D-21-11593R1

Biosafety devices to control the spread of potentially contaminated dispersion particles. New associated strategies for health environments.

Dear Dr. Montalli:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Dr. Amitava Mukherjee

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .